Government to back Bukwang’s anticancer drug development
Published: 2012-05-03 06:56:00
Updated: 2012-05-03 06:56:00
Bukwang Pharmaceutical Co. said Friday that its apatinib mesylate, an investigational cancer drug currently undergoing clinical trials, will receive the government support as part of a government program to cultivate blockbuster drugs, targeting the international market.
Apatinib is a potentia...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
